Covered recipient · General Payments record
JUSTIN S LYMAN
Allopathic & Osteopathic Physicians Internal Medicine Rheumatology
General Payments · PY2018–2023
$1,835.14
- Reported across 90 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2023 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $381.77 | 18 |
By paying entity
PY2023 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $93.95 | 4 |
| Amgen Inc. | $81.44 | 4 |
| PFIZER INC. | $80.52 | 4 |
| Acerta Pharma LLC | $58.60 | 3 |
| UCB, Inc. | $34.67 | 1 |
| GlaxoSmithKline, LLC. | $16.45 | 1 |
| Horizon Pharma plc | $16.14 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2023 (18)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $26.61 | 01/24/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997805385 | CMS |
| ABBVIE INC. | $18.75 | 03/07/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997805387 | CMS |
| ABBVIE INC. | $21.98 | 05/11/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997805389 | CMS |
| ABBVIE INC. | $26.61 | 05/16/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997805391 | CMS |
| Amgen Inc. | $26.16 | 02/02/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1019982917 | CMS |
| Amgen Inc. | $15.34 | 03/09/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1019982923 | CMS |
| Amgen Inc. | $17.80 | 04/03/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1019982919 | CMS |
| Amgen Inc. | $22.14 | 05/02/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1019982921 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.19 | 01/25/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1015943101 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.38 | 02/14/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1015726265 | CMS |
| AstraZeneca Pharmaceuticals LP | $24.03 | 05/11/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1015106189 | CMS |
| GlaxoSmithKline, LLC. | $16.45 | 05/17/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1001434945 | CMS |
| Horizon Therapeutics plc | $16.14 | 03/02/2023 | Food and Beverage | Undisputed | 01/23/2026 | 987040391 | CMS |
| PFIZER INC. | $23.52 | 01/23/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1050564255 | CMS |
| PFIZER INC. | $18.99 | 02/01/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1050409895 | CMS |
| PFIZER INC. | $19.35 | 02/28/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1049517055 | CMS |
| PFIZER INC. | $18.66 | 04/25/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1049118197 | CMS |
| UCB, Inc. | $34.67 | 04/11/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1021669111 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023
- Generated from
- OP_DTL_GNRL_PGYR2023_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.